SEATTLE, Feb. 21, 2023 /PRNewswire/ — According to Coherent Market Insights, the global plasma derived medicine market is estimated to be valued at US$ 33,450 million in 2021 and expected to exhibit a CAGR of 6.8% during the forecast period (2021-2028).
Key Trends and Analysis of the Global Plasma Derived Medicine Market:
Major market players are focusing on adopting inorganic strategies such as acquisitions to expand their product portfolio, which is expected to drive the global plasma derived medicine market growth over the forecast period. For instance, in November 2023, Kamada Pharmaceuticals, a global specialty plasma-derived biopharmaceutical company, announced that it had acquired a portfolio of four plasma-derived hyperimmune commercial products approved by the U.S. Food and Drug Administration (FDA) from Saol Therapeutics, a commercial specialty pharmaceutical company focused on addressing the medical needs of unserved or underserved patient population.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4929
Key Market Takeaways:
The global plasma derived medicine market is expected to exhibit a CAGR of 6.8% during the forecast period due to the increasing adoption of inorganic strategies such as collaborations and agreements by the key market players. For instance, in March 2020, Grifols, S.A., a multinational pharmaceutical and chesmical manufacturer, announced collaboration with the U.S. Biomedical Advanced Research Development Authority (BARDA), the Food and Drug Administration (FDA), and other Federal public health agencies to collect plasma from convalescent COVID-19 patients, process this specific plasma, and carry out the necessary preclinical and clinical studies to determine if anti-SARS-CoV-2 hyperimmune globulin therapy can be used successfully to treat the COVID-19.
Among product types, the immunoglobulins segment is estimated to hold a dominant position in the global plasma derived medicine market over the forecast period, owing to its increased usage in primary immunodeficiency and neurological applications. For instance, in June 2023, Grifols, S.A., a multinational pharmaceutical and chemical manufacturer, began the commercialization of HyperHEP B, a new formulation of immune globulin made from human plasma for hepatitis B postexposure prophylaxis.
On the basis of region, North America is estimated to account for the largest market share in the global plasma derived medicine market over the forecast period owing to the increasing research activities and adoption of strategies such as partnerships by the key players operating in the region. For instance, in April 2020, Kamada Pharmaceuticals, a global specialty plasma-derived biopharmaceutical company, and Kedrion, an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products, announced a global collaboration for the development, manufacturing, and distribution of a human plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a potential treatment for coronavirus patients.
Key players operating in the global plasma derived medicine market include Grifols, S.A., SK Plasma, Fusion Healthcare, Takeda Pharmaceutical Company Limited, LFB, Octapharma AG, CSL Limited, Bio Products Laboratory Ltd., China Biologic Products Holdings, Inc., Kedrion, Shanghai RAAS, ADMA Biologics Inc., Kamada Pharmaceuticals, and Biotest AG.
Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/4929
Detailed Segmentation:
Global Plasma Derived Medicine Market, By Product Type:
- Albumin
- Coagulation factors
- Immunoglobulins
- Others
Global Plasma Derived Medicine Market, By Indication:
- Pelvic Inflammatory Disease (PID)
- Bleeding Disorders
- Alpha-1 Antitrypsin Deficiency (AATD)
- Hereditary Angioedema (HAE)
- Chronic Inflammatory Demyelinating Polyneuropathy
- Guillain-Barre Syndrome
- Multifocal Motor Neuropathy
- Liver Diseases
- Primary Immune Thrombocytopenia
- Infections
- Other Orphan Diseases
Global Plasma Derived Medicine Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Plasma Derived Medicine Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- Europe
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- By Country:
- GCC Countries
- Israel
- South Africa
- Rest of Middle East & Africa
Buy this Complete Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/4929
Find more related trending reports below:
Plasma Therapy Market, By Type (Pure PRP, Leucocyte-rich PRP, Pure Platelet-rich Fibrin (PRF), and Leukocyte-rich Fibrin (L-PRF)), By Application (Infections Diseases, Dental, Nerve Injury, Cardiac Muscle Injury, and Other Applications), By End-User (Hospitals & Clinics, Research Institutes, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
Plasma Protease C1-inhibitor Treatment Market, by Drug Type (C1-inhibitors, Kallikrein Inhibitor, and Selective Bradykinin B2 Receptor Antagonist), by Dosage (Lyophilized and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: [email protected]
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter
SOURCE Coherent Market Insights
